SAĞLIK HİZMETLERİNDE ÖNCELİKLERİN BELİRLENMESİNDE EKONOMİK DEĞERLENDİRME YÖNTEMİ OLARAK MALİYET-ETKİLİLİK ANALİZİ
Öz
Anahtar Kelimeler
Kaynakça
- ANELL, A. “Priority setting for pharmaceuticals: the use of health economic evidence by reimbursement and clinical guidance committees” The European Journal of Health Economics, Vol. 5 (1), 2004, s. 2835.
- BALTUSSEN, R. “Priority setting of public spending in developing countries: Do not try to do everything for everybody”, Health Policy, 78, 2006, s. 149–156.
- BALTUSSEN, R. ve NIESSEN, L. “Priority setting of health interventions: the need for multi-criteria decision analysis”, Cost Effectiveness and Resource Allocation, 4:14, 2006, s. 1-9.
- BROUWER, W. B. F. vd. “Welfarism vs. extra-welfarism”, Journal of Health Economics, 27, 2008, s. 325-338.
- COAST, J. “Is economic evaluation in touch with society's health values?”, British Medical Journal, 329, 2004, s. 1233-1236.
- COAST, J. vd. “Welfarism, extra-welfarism and capability: The spread of ideas in health economics”, Social Science and Medicine, 67, 2008, s. 1190-1198.
- CORNAGO, D. vd. “Pharmacoeconomic studies in Italy: a critical review of the literature”, The European Journal of Health Economics, Vol. 8, 2007, s. 89-95.
- CORNUZ, J. vd. “Cost-effectiveness analysis of the first-line therapies for nicotine dependence”, European Journal of Clinical Pharmacology, 59 (3), 2003, s. 201-206.
Ayrıntılar
Birincil Dil
Türkçe
Konular
-
Bölüm
-
Yazarlar
Yrd.Doç.Dr.Zafer Çalışkan
Bu kişi benim
Yayımlanma Tarihi
1 Haziran 2009
Gönderilme Tarihi
12 Haziran 2015
Kabul Tarihi
-
Yayımlandığı Sayı
Yıl 2009 Cilt: 14 Sayı: 2